Skip to main content
SpringerLink
Log in
Book cover

Neuro-Psychopharmaka Ein Therapie-Handbuch pp 17–57Cite as

Pharmakologie

  • Chapter

  • 30 Accesses

Zusammenfassung

Die pharmakokinetischen Einflußgrößen der Neuroleptikawirkung sind in Abb. 2.1.1 dargestellt. Während stark polare oder hydrophile Substanzen einem Ein-Kompartment-Modell folgen, sind zur Beschreibung der pharmakokinetischen Verhältnisse lipophiler Substanzen wie der Neuroleptika Multi-Kompartment-Modelle notwendig. Nach Resorption eines oral gegebenen Neuroleptikums kommt es zu einer teilweisen präsystemischen Verstoffwechselung, die bei parenteraler Gabe z. B. eines Depotneuroleptikums umgangen werden kann. Aus dem Plasma wird das Pharmakon in die verschiedenen Kompartimente verteilt und dort gebunden, in der Leber metabolisiert und renal sowie biliär ausgeschieden. Nur der Anteil des Neuroleptikums, der nicht an Plasmaproteine gebunden ist, also in freier Form vorliegt, kann mit dem Hirngewebe und dem Liquorraum im Gleichgewicht stehen. An einem idealisierten Plasmaspiegel-Kurvenverlauf (Abb. 2.1.2) lassen sich eine initiale Absorptionsphase, die Verteilung und Äquilibrierung mit den einzelnen Körperkompartimenten, die Elimination sowie das Zurückfluten aus den äquilibrierenden Kompartimenten unterscheiden.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aaesjorgensen T (1981) Serum concentrations of cis(Z)- and trans(E)-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers. Acta Psychiatr Scand [Suppl] 294: 64–69

    CAS  Google Scholar 

  2. Aaesjorgensen T, Overo KF, Bobeso KP, Jorgensen A (1977) Pharmacokinetic studies on clopenthixol decanoate: a comparison with clopenthixol in dogs and rats. Acta Pharmacol Toxicol 41: 103–120

    CAS  Google Scholar 

  3. Alfredsson G, Bjerkenstedt L, Edman G, Härnryd C, Oxenstierna G, Sedvall G, Wiesel FA (1984)

    Google Scholar 

  4. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta Psychiatr Scand 69 [Suppl 3111: 49–74

    Google Scholar 

  5. Altamura AC, Mauri M, Cavallaro R, Regazetti MG, Barbeggi SR (1989) Hydroxyhaloperidol and clinical outcome in schizophrenia. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 263–268

    Google Scholar 

  6. Amdisen A, Aesjorgensen T, Thomsen NJ, Madsen VT, Neilsen Ms (1986) Serum concentrations and clinical effect of zuclopenthixol in acutely disturbed, psychotic patients treated with zuclopenthixol acetate in viscoleo. Psycho-pharmacology 90: 412–416

    CAS  Google Scholar 

  7. Angrist B, Sathananthan G, Gershon S (1973) Behavioral effects of L-dopa in schizophrenic patients. Psychopharmacologia 31: 1–12

    PubMed  CAS  Google Scholar 

  8. Bahr Von C, Guengerich FP, Movin G, Nordin C

    Google Scholar 

  9. The use of human liver banks in pharmacogenetic research. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 163–171

    Google Scholar 

  10. Balant-Gorgia AE, Balant L (1987) Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokin 149: 65–90

    Google Scholar 

  11. Baldessarini RJ, Cohen BM, Tricher MI-1 (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79–91

    PubMed  CAS  Google Scholar 

  12. Bamrah JS, Kumar V et al. (1986) Interactions between procyclidine and neuroleptic drugs. Br J Psychiatry 149: 726–733

    Google Scholar 

  13. Ban THA (1987) Drug interactions in psychiatry. Int Pharmacopsychiatry 13: 94–99

    Google Scholar 

  14. Ban MLA (1979) Adverse effects in maintenance treatment: practical and theoretical considerations. Prog Neuropsychopharmacol 3: 231–244

    PubMed  CAS  Google Scholar 

  15. Bevilacqua R, Benassi CA, Largajolli R, Veronese FM (1979) Psychoactive butyrophenones: binding to human and bovine serum albumin. Pharmacol Res Commun 11 (5): 447–454

    PubMed  CAS  Google Scholar 

  16. Bigelow LB,Hirsch DG, Braun T, korpi ER, Wagner

    Google Scholar 

  17. RL, Zaleman S, WYAI-r RJ (1985) Absence of a relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed dose study. Psychopharmacol Bull 21: 66–68

    Google Scholar 

  18. Bird HA, Legallez P, Wright V (1983) Drowsiness due to haloperidol/indomethacin in combination. Lancet i: 830–831

    Google Scholar 

  19. Blazer HG, Federspiel CF, RAY WA et al. (1983) The risk of anticholinergic toxicity in the elderly: a study of prescribing practices in two populations. J Gerontol 38: 31–35

    PubMed  Google Scholar 

  20. Borgström L, Larsson H, Molander L (1982) Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol 23: 173–176

    PubMed  Google Scholar 

  21. Breyer-Pfaff U (1980) Antipsychotics: metabolism and kinetics. In: HOFFMEISTER F, STILLS G (eds) Handbook of experimental pharmacology, vol 5. Springer, Berlin Heidelberg New York, pp 287–304

    Google Scholar 

  22. Breyer-Pfaff U, Giedke H, Nill K, Schied HW (1988) Neuere Befunde zur Pharmakokinetik von Perazin und verwandten Phenothiazinen. In: Helmchen H, Hippius H, Tolle R (Hrsg) Therapie mit Neuroleptika–Perazin. Thieme, Stuttgart New York, S 18–23

    Google Scholar 

  23. Breyer-Pfaff U, Nill K, Schied HW, Gaertner HJ, Giedke H (1988) Single-dose kinetics of the neuroleptic drug perazine in psychotic patients. Psychopharmacology 95: 374–377

    CAS  Google Scholar 

  24. Brodie BB (1967) Psychochemical and biochemical basis of pharmacology. JAMA 202: 600–609

    CAS  Google Scholar 

  25. Browning JL, Silverman PB, Harrington CA, DAMS LM (1982) Preliminary behavioural and pharmacological studies on the haloperidol metabolite reduced haloperidol. Soc Neurosci Abstr 8: 470

    Google Scholar 

  26. Burrows GH, Norman TR (1980) Psychotherapeutic drugs: important adverse reactions and interactions. Drugs 20: 485–493

    PubMed  CAS  Google Scholar 

  27. Bylund DB (1981) Interactions of neuroleptic metabolites with dopaminergic, alpha adrenergic and muscarinic cholinergie receptors. J Pharmacol Exp Ther 217: 81–86

    PubMed  CAS  Google Scholar 

  28. Casat CD, Wilson DC (1986) Tics with combined thioridazinemethylphenidate therapy: case report. J Clin Psychiatry 47: 44 45

    Google Scholar 

  29. Casper R, Garver DL, Dekirmenjian H, Chang S, Davis JM (1980) Phenothiazine levels on plasma and red blood cells. Arch Gen Psychiatry 37: 301305

    Google Scholar 

  30. Cheeseman HJ, Neal MJ (1981) Interactions of chlorpromazine with tea and coffee. Br J Clin Pharmacol 12: 165–169

    PubMed  CAS  Google Scholar 

  31. COFFEY E, Ross DR (1980) Treatment of lithium/ neuroleptic neurotoxicity during lithium maintenance. Am J Psychiatry 137: 736–737

    PubMed  CAS  Google Scholar 

  32. Cohen SN, Armstone MF (1974) Drug interactions. Williams & Wilkins, Baltimore

    Google Scholar 

  33. Cohen WJ, Cohen NH (1974) Lithium carbonate, haloperidol and irreversible brain damage. J Am Med Assoc 230: 1283–1288

    CAS  Google Scholar 

  34. Cohen BM, Herschel M, Aoba A (1979) Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites. Psychiatr Res 1: 199–208

    CAS  Google Scholar 

  35. Cohen BM, Lapinski JF, Pope HG, Harris PQ, Allesman RI (1980) Neuroleptic blood levels and therapeutic effect. Psychopharmacology (Berlin) 70: 191–193

    CAS  Google Scholar 

  36. Contreras S, Alexander H, Faber R, Bowden C (1987) Neuroleptic radioreceptor activity and clinical outcome in schizophrenia. J Clin Psychopharmacol 7: 95–98

    PubMed  CAS  Google Scholar 

  37. Cooper S, Laber JM, Dugal R et al. (1979) Gas chromatographic determination of amitriptyline and perphenazine in plasma of schizophrenic patients after administration of the combination of amitriptyline with perphenazine. Arzneimittelforschung 29: 158–161

    PubMed  CAS  Google Scholar 

  38. Coper H (1979) Wechselwirkungen von Psychopharmaka mit anderen Medikamenten. Nervenarzt 50: 485–490

    Google Scholar 

  39. Cressman WA, Bianchine JR, Slotnick VB, Johnson PC

    Google Scholar 

  40. Plostnieks J (1974) Plasma level profile of haloperidol in man following intramuscular administration. Eur J Clin Pharmacol 7: 99–103

    PubMed  Google Scholar 

  41. Cressman WA, Plostnieks J, Johnson PC (1973) Absorption, metabolism and excretion of droperidol by human subjects following intramuscular and intravenous administration. Anesthesiology 38: 363–369

    PubMed  CAS  Google Scholar 

  42. Curry SH, Whelpton R, De Schepper PJ, Vrancks S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7: 325–331

    CAS  Google Scholar 

  43. Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442

    PubMed  CAS  Google Scholar 

  44. Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448

    PubMed  CAS  Google Scholar 

  45. Dahl SG (1986) Plasma level monitoring of anti-psychotic drugs. Clinical utility. Clin Pharmacokinet 11: 36–61

    PubMed  CAS  Google Scholar 

  46. Dahl SG (1990) Pharmakokinetik der Neuroleptika. In: Müller-Oerlinghausen, Müller HJ

    Google Scholar 

  47. Ruther E (Hrsg) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Tokyo, S 25–33

    Google Scholar 

  48. Davis JM, Janowski DS et al. (1973) The psycho-pharmacology of methylphenidate in man. In: BAN TA et al. (eds) New psychopharmacology. Sexual disorders and drug abuse. Elsevier Amsterdam, pp 675–681

    Google Scholar 

  49. Diehl LW (1985) Die Bedeutung der Blutspiegeluntersuchungen für die Therapie epileptischer Verstimmungen und Psychosen. Nervenarzt 56: 383–387

    PubMed  CAS  Google Scholar 

  50. Dysken NW, Javaid JI, Ciang SS, Shaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berlin) 73: 205–210

    Google Scholar 

  51. El-Assra A, El-Sosky A, Kaye N, Blain PG, Wiles DH, Hajioff J, Gould SE (1983) The change from oral to depot neuroleptics in chronic schizophrenia. Clinical response and plasma levels after treatment with bromperidol or fluphenazine decanoate. Janssen Res Rep

    Google Scholar 

  52. Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (1984) Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry (Sec 2 ) 45: 50–59

    Google Scholar 

  53. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards ALet al. (1985) Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 20: 329–332

    PubMed  CAS  Google Scholar 

  54. Evans D, Rogers J, Peiper S (1979) Intestinal dilation associated with phenothiazine therapy: a case report and literature review. Am J Psychiatry 136: 970–972

    PubMed  CAS  Google Scholar 

  55. Farde L, Wiesel FA, Nilsson L, Sedvall G (1989) The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 32–39

    Google Scholar 

  56. Forsman A, Ohman R (1976) Pharmacokinetic studies on haloperidol in man. Gun Ther Res 20: 319–336

    CAS  Google Scholar 

  57. Forsman A, Ohman R (1977) Applied pharmacokinetics of haloperidol in man. CM Ther Res21: 396–411

    Google Scholar 

  58. Furlanut M, Benetello P, Perosa A, Colombo G, Gallo F, Forgione A (1988) Pharmacokinetics of benperidol in volunteers after oral administration. Int J Clin Pharm Res 8: 13–16

    CAS  Google Scholar 

  59. Gaebel W, Pietzcker A, Ulrich G, Schley J, Müller oerlinghausen B (1988) Predictors of neuroleptic treatment response in acute schizophrenia: results of a treatment study with perazine. Pharmacopsychiatry 21: 384–386

    PubMed  CAS  Google Scholar 

  60. Gardos G, Cole JO (1983) Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 140: 200–202

    PubMed  CAS  Google Scholar 

  61. Garver DL (1989) Neuroleptic drug levels in erythrocytes and in plasma: implications for therapeutic drug monitoring. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo, pp 244–256

    Google Scholar 

  62. Gaultieri CT, Powell SF (1978) Psychoactive drug interactions. J Clin Psychiatry 39: 720–729

    PubMed  CAS  Google Scholar 

  63. Georgotas A, Serra MT, Green DE, Perel JM, Gershon S, Forrest Is (1979) Chlorpromazine excretion. 3. Fecal excretion of 14C-chlorpromazine in chronically dosed patients. Commun Psychopharmacol 3: 197–202

    PubMed  CAS  Google Scholar 

  64. Gerlach J, Thorsten K (1976) The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. Int Pharmacopsychiatry 11: 1–7

    PubMed  CAS  Google Scholar 

  65. Gilman AG, Goodman LS, Rall TW, Murad F (1980) The pharmacological basis of therapeutics, 7 ed. Macmillan, New York

    Google Scholar 

  66. Girard M, Granter F, Schmitt L, Cotonat J, Escande M, Blanc M (1984) Premiers résultats d’une étude pharmacocinétique de la pipothiazine dt de son ester palmitique (Piportil L4) dans une population de schizophrenes. Encephale 10: 171–176

    PubMed  CAS  Google Scholar 

  67. Gold MI (1974) Profound hypotension associated with preoperative use of phenothiazines anaesthesia and analgesia. Curr Res 53: 844–848

    CAS  Google Scholar 

  68. Goldstein SA, Van-Vunakis H (1981) Determination of fluphenazine, related phenothiazine drugs and metabolites by combined high-performance liquid chromatography and radio-immunoassay. J Pharmacol Exp Ther 217: 36–43

    PubMed  CAS  Google Scholar 

  69. Goon M (1981) Reversibility of longterm tardive dyskinesia associated with antiparkinsonian medication: a case report. Am J Psychiatry 138: 1112–1113

    Google Scholar 

  70. Graham-Smith DG (ed) (1977) Drug interactions. University Park Press, Baltimore

    Google Scholar 

  71. GRAM LF, BROSEN K (1989) Inhibitors of the microsomal oxidation of psychotropic drugs: selectivity and clinical significance. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo, pp 172–180

    Google Scholar 

  72. Grell W, Haag H, Rossnagl G, Rüther E (1984) Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 145: 304–310

    Google Scholar 

  73. Hansen CB, Larsen NE, Gulmann N (1982) Doseresponse relationship of perphenazine in the treatment of acute psychoses. Psychopharmacology 27: 112–115

    Google Scholar 

  74. Hansten PD (1975) Arzneimittelinteraktionen. Hippokrates, Stuttgart

    Google Scholar 

  75. Hansten PD (1981) Arzneimittel-Interaktionen: wie wirken Medikamente auf andere Medikamente, auf Labordaten, auf klinische Befunde. Hippokrates, Stuttgart

    Google Scholar 

  76. Haring C, Fleischhacker WW Scheu P, Humpel C, Barnas C, Saria A (1990) Influence of patient-related variable on clozapine plasma levels. Am J Psychiatry 147: 1471–1475

    CAS  Google Scholar 

  77. Helmchen H, Müller-Oerlinghausen B (1981) Die Kombination von Antidepressiva mit anderen Medikamenten. Fortschr Neurol Psychiat 49: 371–379

    PubMed  CAS  Google Scholar 

  78. Hobbs DC, Welch WM, Short MJ, Moody WA, Van Der Velde CD (1974) Pharmacokinetics of thiothixene in man. Clin Pharmacol Ther 16: 473478

    Google Scholar 

  79. Hollister LE (1972) Clinic of psychotherapeutic drugs. I. Antipsychotic and antimanic drugs. Drugs 4: 321–360

    PubMed  CAS  Google Scholar 

  80. Hollister LE (1975) Hydroxyzine hydrochlorid. Possible adverse cardiac interactions. Psychopharmacol Commun 1: 61–65

    PubMed  CAS  Google Scholar 

  81. Hurwitz A (1977) Antacid therapy and drug kinetics. Clin Pharmacokinet 2: 269–280

    PubMed  CAS  Google Scholar 

  82. Imondi AR, Alam AS, Brennan JJ, Hagerman LM (1978) Metabolism of sulpiride in man and rhesus monkeys. Arch Int Pharmacodyn 232: 79–91

    PubMed  CAS  Google Scholar 

  83. Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10: 315–333

    PubMed  CAS  Google Scholar 

  84. Jann MW, Saklad STRet al. (1986) Effects of smoking on haloperidol and reduced haloperidol plasma concentration and haloperidol clearance. Psychopharmacology 90: 468–470

    PubMed  CAS  Google Scholar 

  85. Janowsky DS, El-Youssef MK, Davis JMet al. (1973) Antagonism of guanethedine by chlorpromazine. Am J Psychiatry 130: 808–812

    PubMed  CAS  Google Scholar 

  86. Janowsky DS, Davis JB (1976) Methylphenidate, dextroamphetamine, levamphetamine effects in schizophrenic symptoms. Arch Gen Psyachiatry 33: 304–388

    CAS  Google Scholar 

  87. Jorgensen A, Andersen J, Bjorndal N, Dencker SJ, Lundin L, Malm U (1982) Serum concentrations of cis(Z)-flupenthixol and prolactin in chronic schizophrenic patients treated with flupenthixol and cis(Z)-flupenthixol decanoate. Psychopharmacology 77: 58–65

    CAS  Google Scholar 

  88. Jorgensen A, Gottfries CG (1972) Pharmacokinetic studies on flupenthixol and flupenthixol decanoate in man using tritium labelled compounds. Psychopharmacology 27: 1–10

    CAS  Google Scholar 

  89. Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: BRIDGES JW, CHASSEAUD LF (eds) Progress in drug metabolism, vol 9. Taylor & Francis, London, pp 111174

    Google Scholar 

  90. Jorgensen A, Aesjorgensen T (1988) Pharmacokinetic variations of zuclopenthixol and flupentixol administered orally or intramuscularly as retard or depot formulations. Nord Psychiatr Tidsskr 42: 501–502

    Google Scholar 

  91. Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanisms of the antipsychotic effect in the treatment of acute schizophrenia. Lancet i: 848–851

    Google Scholar 

  92. Kapfhammer HP (1990) Umstellungsregime von Kurzzeit-auf Depotneuroleptika. In: Müller-Oerlinghausen, Müller HJ, Rüther E (Hrsg) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Tokyo, S 173–196

    Google Scholar 

  93. Khan AR (1969) Some aspects of clopenthixol metabolism in rats and humans. Acta Pharmacol Toxicol 27: 202–212

    CAS  Google Scholar 

  94. Knudsen P, Vierar T (1984) Cannabis and neuro-leptic agents in schizophrenia. Acta Psychiatr Scand 69: 162–174

    PubMed  CAS  Google Scholar 

  95. Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand [Suppl 3221 72: 51–75

    Google Scholar 

  96. Knudsen P, Hansen LB, Larsen AE (1985) Depot neuroleptic treatment: clinical and pharmacokinetic studies of perphenazine decanoate. Acta Psychiatr Scand [Suppl 3221: 5–50

    Google Scholar 

  97. Kopera H (1977) Wechselwirkungen von Arzneimitteln. Pharm Acta Helv 52: 79–88

    PubMed  CAS  Google Scholar 

  98. Kopera H (1986) Interferenzen und Störwirkungen von Psychopharmaka und anderen Medikamenten. In: Hinterhuber H, Schubert N, Kulhanek F (Hrsg) Seiteneffekte und Störwirkungen der Psychopharmaka. Schattauer, Stuttgart New York, S 29–42

    Google Scholar 

  99. Korpi Er, Wyatt RJ (1984) Reduced haloperidol: effects on striatal dopamine metabolism and conversion to haloperidol in the rat. Psychoharmacology (Berlin) 83: 34–37

    CAS  Google Scholar 

  100. Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Reduced haloperidol in the post mortem brains of haloperidol treated patients. Psychiatry Res 11: 259–269

    Google Scholar 

  101. Kragh-Sorensen P, Borga O, Gasle Net al. (1977) Effect of simultaneous treatment with low dose of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline. Eur J Clin Pharmacol 11: 479–483

    PubMed  CAS  Google Scholar 

  102. Lasswell Wj, Weber STS, Wilkins JM (1984) In vitro interaction of neuroleptics and tricyclic antidepressants with coffee, tea and gallotaunic acid. J Pharm Sci 73: 1056–1058

    PubMed  CAS  Google Scholar 

  103. Linkowski P, Hubain P, Von Frenckell R, Mendlewicz J (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatry Neurol Sci 234: 231–236

    PubMed  CAS  Google Scholar 

  104. Linnoila M, George L, Guthisie S (1982) Interaction between antidepressants and phenothiazine in psychiatric inpatients. Am J Psychiatry 138: 1329–1331

    Google Scholar 

  105. Loi CM, Vestal RE (1988) Drug metabolism in the elderly. Pharmacol Ther 36: 131–149

    PubMed  CAS  Google Scholar 

  106. Loudon JB, Waring H (1976) Toxic reactions to lithium and haloperidol. Lancet ii: 1088

    Google Scholar 

  107. Louzaneto MR, Müller-Spahn F, Rüther E, Scherer J (1988) Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry 21: 226–231

    CAS  Google Scholar 

  108. Marder SR, Putten Van T, Aravagiri M (1989) Plasma level monitoring for maintenance neuroleptic therapy. In: DAHL SG, GRAM LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo, pp 269–279

    Google Scholar 

  109. Martensson E, Roos BE (1973) Serum levels of thioridazine in psychiatric patients and healthy volunteers. Eur JClinPharmacol 6: 181–186

    CAS  Google Scholar 

  110. Martensson E, Nyberg G (1989) Active metabolites of neuroleptics in plasma and CSF: implications for therapeutic drug monitoring. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. From molecular studies to clinical reality. Springer, Berlin Heidelberg New York Tokyo, pp 257–262

    Google Scholar 

  111. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berlin) 81: 354–356

    Google Scholar 

  112. Mavroidis ML, Garver DL, Kanter DR, Hirschowitz J (1984a) Fluphenazine plasma levels and clinical response. J Clin Psychiatry 45: 370–373

    Google Scholar 

  113. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984b) Clinical relevance of thiothixene plas- ma levels. J Clin Psychopharmacol 4: 155–157

    PubMed  CAS  Google Scholar 

  114. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984c) Therapeutic blood levels of fluphenazine: plasma or RBC determinations? Psychopharmacol Bull 20: 168–170

    PubMed  CAS  Google Scholar 

  115. Mcgennis AJ (1983) Hazards of lithium and neuroleptics in schizo-affective disorders. Br J Psychiatry 142: 99–100

    PubMed  CAS  Google Scholar 

  116. Meier PJ (1985) Alkohol, Alkoholismus and Arzneimittel. Schweiz Med Wochenschr 115: 1792

    PubMed  CAS  Google Scholar 

  117. Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKAY G (1987) The search for correlations between neuroleptic plasma levels and clinical outcome: a critical review. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1341–1351

    Google Scholar 

  118. Migdalof BH, Grindel JM, Heykants JJP, Janssen PAJ (1979) Penfluridol: a neuroleptic drug designed for long duration of action. Drug Metabol Rev 9: 281–299

    CAS  Google Scholar 

  119. Mikkelsen EJ (1979) Caffeine and schizophrenia. J Clin Psychiatry 39: 732–735

    Google Scholar 

  120. Morselli PL, Bianchetti G, Durand G, Le Henzey MF, Zarifian Eet al. (1979) Haloperidol plasma levels monitoring in pediatric patients. Ther Drug Monit 1: 35–46

    PubMed  CAS  Google Scholar 

  121. Overo KF, Gram LF, Hansen V (1977) Interaction of perphenazine with kinetics of nortriptyline. Acta Pharmacol Toxicol 40: 97–105

    CAS  Google Scholar 

  122. Peet M, Middlemiss DN, Yates RH (1981) Propranolol in schizophrenia. II. Clinical and bioche- mical aspects of combining propranolol with chlorpromazine. Br J Psychiatry 139: 112–117

    Google Scholar 

  123. Piafsky KM, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F (1978) Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alphasub 1 acid glycoprotein. N Engl J Med 299: 1435–1439

    PubMed  CAS  Google Scholar 

  124. Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21: 59–61

    PubMed  CAS  Google Scholar 

  125. Proakis AG, Borowitz JL (1974) Blockage of insulin release by certain phenothiazines. Biochem Pharmacol 23: 1693–1700

    PubMed  CAS  Google Scholar 

  126. Pühringer W, Kocher R, Gastpar M (1979) Zur Frage der Inkompatibilität einer Lithium-Neuroleptika-Kombinationstherapie. Nervenarzt 50 (2): 124–127

    PubMed  Google Scholar 

  127. Puiitn T Van, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734

    Google Scholar 

  128. Putten T Van, Marder SR, May PRA, Poland RE, O’brien RP (1985) Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 21: 69–72

    Google Scholar 

  129. Raaflaub J (1975) On the pharmacokinetics of chlorprothixene in man. Experimentia 31: 557–558

    CAS  Google Scholar 

  130. Ragheb M (1981) Drug interactions in psychiatric practice. Int harmacopsychiatry 16: 92–118

    CAS  Google Scholar 

  131. Rawlins MD (1978) Drug interactions and anaesthesia. Br J Anaesth 50: 689–693

    PubMed  CAS  Google Scholar 

  132. Rivera-Calimlin L (1976) Impaired absorption of chlorpromazin in rats given trihexyphenidyl. Br J Pharmacol 56: 301–305

    Google Scholar 

  133. Rivera-Calimlin L, Kerzner B, KARCH FE (1978) Effects of lithium on plasma chlorpromazine levels. Clin Pharmacol Ther 23: 451–455

    Google Scholar 

  134. Rivera-Calimlin L, Nasrallah H, Strauss Jet al. (1976) Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 133: 646–652

    Google Scholar 

  135. Rivera-Calimlim L, Gift T, Nasrallah H, WYATT RJ, Lasagna L (1978) Low plasma levels of CPZ in patients chronically treated with neuroleptics. Comm Psychopharmacol 2: 113–121

    CAS  Google Scholar 

  136. Sayers AC, Amsler HA (1977) Clozapine. In: Goldberg ME (ed) Pharmacological and biochemical properties of drug substances, vol 1. Am Pharmaceut Ass, Acad Pharmaceut Sciences, pp 1–31

    Google Scholar 

  137. Schwinghammer TL, Juhl RP, Dittert LW, Melethil SK, Kroboth FJ, Chungi VS (1984) Comparison of the bioavailabilitity of oral, rectal and intramuscular promethazine. Biopharm Drug Dispos 5: 185–194

    PubMed  CAS  Google Scholar 

  138. Shukla S, Gogwin CHD, Long LEB, Miller MG (1984) Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 141: 1604–1606

    PubMed  CAS  Google Scholar 

  139. Shvartsburd A, Nowkeafor V Smith RC (1984) Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients. Psychopharmacology 82: 55–61

    PubMed  CAS  Google Scholar 

  140. Sieberns S (1990) Neuroleptika–Interaktionen mit anderen Arzneimitteln. In: Muller-Oerlinghausen B, Möller HJ, Rüther E (Hrsg) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York Toyko, S 37–45

    Google Scholar 

  141. Singh MM, Kay SR (1975) Therapeutic reversal with benzotropine in schizophrenic. J Nery Ment Dis 160: 258–305

    CAS  Google Scholar 

  142. Siris SG, Copper TB, Rifkin AEet al. (1982) Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate. Am J Psychiatry 139: 104–106

    PubMed  CAS  Google Scholar 

  143. Sitar DS (1989) Human drug metabolism in vivo. Pharmacol Ther 43: 363–375

    PubMed  CAS  Google Scholar 

  144. Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, DEJoHN C (1984a) Halo- peridol plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical versus radioreceptor plasma level assays. Arch Gen Psychiatry 41: 1044–1049

    CAS  Google Scholar 

  145. Smith RC, Baumgartner R, Ravajondron GK, Shvartsburd A, Schoolar JC, Allen R, Johnson R (1984b)

    Google Scholar 

  146. Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Psychiatry Res 12: 287–296

    Google Scholar 

  147. Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M (1985) Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull 21: 52–59

    PubMed  CAS  Google Scholar 

  148. Smith RC, Baumgartner R, Shvartsburd A, Ravichandran GK, Vroulis G, Mauldin M (1985) Compa-rative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Psychopharmacology 85: 449–455

    PubMed  CAS  Google Scholar 

  149. Spring G, Frankel M (1981) New data in lithium and haloperidol incompatibility. Am J Psychiatry 138: 818–821

    PubMed  CAS  Google Scholar 

  150. Stafford JR, Fann WE (1977) Drug interactions with guanidinium antihypertensives. Drugs 13: 57–65

    PubMed  CAS  Google Scholar 

  151. Staniforth DH, Yorkston NJ, Zaki SA (1982) Dose dependent changes in propranolol half life when used as an adjunct to neuroleptic treatment. Psychopharmacology 76: 62–65

    PubMed  CAS  Google Scholar 

  152. Strolin-Benedetti M, Donath A, Frigerio A, Morgan KT, Laville C, Malnoe A (1978) Absorption, elimination et metablisme du tiapride (FLO 1347), medicament neuroleptique, chez le rat, le chien et l’homme. Ann Pharm Fr 36: 279–288

    PubMed  CAS  Google Scholar 

  153. Sunderland T, Cohen BM (1987) Blood to brain distribution of neuroleptics. Psychiatr Res 20: 299–305

    CAS  Google Scholar 

  154. Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, Seeman P (1984) Total and free plasma neuroleptic levels in schizophrenic patients. Psychiatr Res 13: 285–293

    CAS  Google Scholar 

  155. Tischio J, Chaikin P, Abrams L, Hetyei N, Patrick J, Weintraub H, Collins D, Chasin M, Wesson D

    Google Scholar 

  156. Abuzzahab F (1982) Comparative bioavailability and pharmacokinetics of bromperidol in schizophrenic patients following oral administration. J Clin Pharmacol 22: 16a

    Google Scholar 

  157. Tord M, Metruda Oet al. (1981) Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nery Ment Dis 169: 324–327

    Google Scholar 

  158. Turano P, Turner WJ, Manian AA (1973) Thin-layer chromatography of chlorpromazine metaboli- tes. Attempt to identify each of the metabolites appearing in blood, urine and feces of chronically medicated schizophrenics. J Chrom 75: 277–293

    Google Scholar 

  159. Usdin E (1971) The assay of chlorpromazine and metabolites in blood, urine, and other tissues. CRC Crit Rev Lab Sci 2: 347–391

    CAS  Google Scholar 

  160. Vranckx-Haenen J, Munter De W, Heykants J (1979) Fluspirilen administered in a biweekly dose for the prevention of relapses in chronic schizophrenics. Acta Psychiatr Belg 79: 459–474

    Google Scholar 

  161. Waller DG, Edwards JG, Polek A (1985) Neuroleptics, lithium and renal function. Br J Psychiatry 146: 510–514

    PubMed  CAS  Google Scholar 

  162. Westlake R, Rastegard A (1973) Hyperpyrexia from drug combinations. JAMA 225: 1250

    Google Scholar 

  163. Wiesel FA, Alfredsson G, Ehrnebo M, Sedvall G (1980) The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacology 17: 385–391

    CAS  Google Scholar 

  164. Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol 8: 565–570

    PubMed  CAS  Google Scholar 

  165. Wiles D (1981) Preliminary assessment of a calf caudate radioreceptor assay for the estimation of neuroleptic drugs in plasma: comparison with other techniques. In: USDIN EJ et al. (ed) Clinical pharmacology in psychiatry: neuroleptic and antidepressant research. Macmillan, London, pp 111–121

    Google Scholar 

  166. Wiles DH, Mccreadie RG, Whitehead A (1990) Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. Psychopharmacology 101: 274–281

    PubMed  CAS  Google Scholar 

  167. Wistedt B, Jorgensen A, Wiles DH (1982) A depot neuroleptic withdrawal and relapse frequency. Psychopharmacology 78: 301–304

    PubMed  CAS  Google Scholar 

  168. Wistedt B, Johanivesz G, Omerhodzic M, Arthur H, Bertilsson L, Petters I (1984) Plasma haloperidol levels and clinical response in acute schizophrenia. Nord Psykiat Tidsskr 9: 13

    Google Scholar 

  169. Wode-Helgodt B, Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed doses. Psychopharmacology 73: 55–62

    PubMed  CAS  Google Scholar 

  170. Wode-Helgodt B, Borg S, Fryo B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychiatric patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58: 149–173

    PubMed  CAS  Google Scholar 

  171. Yesavage JA, Holman CA, Cohn R (1981) Correlation of thiothixene serum levels and age. Psychopharmacology 27: 170–172

    Google Scholar 

  172. Van Zwieten PA (1977) Wechselwirkungen zwischen Antihypertensiva and Psychopharmaka. Pharmakopsychiatry 10: 232–238

    Google Scholar 

  173. Berger HJC, Hoof Van JJM, Spaendonck Van KPM, Horstink MWI, Bercken Van Den JHL, Jaspers R, Cools AR (1989) Haloperidol and cognitive shifting. Neuropsychologia 27: 629–639

    PubMed  CAS  Google Scholar 

  174. Bracha HS (1987) Asymmetric rotational (circling) behavior, a dopamine-related asymmetry; preliminary findings in unmedicated and never-medicated schizophrenic patients. Biol Psychiatry 22: 995–1003

    PubMed  CAS  Google Scholar 

  175. Bunney BS, Sesack SR, Silva NI. (1987) Midbrain dopaminergic systems: neurophysiology and electrophysiological pharmacology. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 113–126

    Google Scholar 

  176. Carlsson A (1987) Overview of dopamine mechanism: neurochemical and pharmacological evidence. In: HELMCHEN H, HENN H (eds) Biological perspectives of schizophrenia. Wiley, Chichester New York, pp 283–297

    Google Scholar 

  177. Cheung H (1981) Schizophrenics fully remitted on neuroleptics for 3 to 5 years — to stop or continue drugs? Br J Psychiatry 138: 490–494

    PubMed  CAS  Google Scholar 

  178. Cohen BM, Lipinksi JF, Pope HG, Harris PQ, Altesman RI (1980) Neuroleptic blood levels and therapeutic effect. Psychopharmacology 70: 19 1193

    Google Scholar 

  179. Collard J (1974) The main clinical classifications of neuroleptics. Acta Psychiatr Scand 74: 447461

    Google Scholar 

  180. Coppola R, Herrmann WM (1987) Psychotropic drug profiles: comparisons by topographic maps of absolute power. Neuropsychobiology 97–104

    Google Scholar 

  181. Creese I (1985) Binding interactions of neuroleptic drugs with dopamine receptors and their implications. In: Seiden LS, Balster RL (eds) Behavioral pharmacology. The current status. Liss, New York, pp 221–241

    Google Scholar 

  182. Davis JM (1985) Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 46: 18–21

    PubMed  CAS  Google Scholar 

  183. Davis JM, Janowsky DS, Sekerke HJ, Manier H, El-Youseff MK (1974) The pharmacokinetics of butaperazine in serum. In: Forrest IS, Carr CJ, Usdin E (eds) Phenothiazines and structurally related drugs. Raven Press, New York, pp 433–443

    Google Scholar 

  184. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 7087

    Google Scholar 

  185. Deniker P (1988) Die Geschichte der Neuroleptika. In: Linde OK (Hrsg) Pharmakopsychiatrie im Wandel der Zeit. Tilia, Nürnberg, S 119–133

    Google Scholar 

  186. Elkayam U, Frishman W (1980) Cardiovascular effects of phenothiazines. Am Heart J 100: 397401

    Google Scholar 

  187. Farde L (1988) Central d2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76

    PubMed  CAS  Google Scholar 

  188. Fibiger HC, Phillips AG (1985) Behavioral pharmacology of neuroleptic drugs: possible mechanism of action. In: SEIDEN LS, BALSTER RL (eds) Behavioral pharmacology. The current status. Liss, New York, pp 243–259

    Google Scholar 

  189. Flügel F, Bente D (1956) Das akinetisch-abulische Syndrom und seine Bedeutung für die pharmakologisch-psychiatrische Forschung. Dtsch Med Wochenschr 81: 2071–2074

    PubMed  Google Scholar 

  190. Frith CD (1987) The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med 17: 631–648

    PubMed  CAS  Google Scholar 

  191. Gaebel W, Pietzcker A, Ulrich G, Schley J, müller-

    Google Scholar 

  192. Oerlinghausen B (1988) Möglichkeiten der Voraussage des Erfolges einer Akutbehandlung mit Perazin anhand der Reaktion auf eine Perazintestdosis. In: Helmchen H, Hippius H, Tolle R (Hrsg) Therapie mit Neuroleptika — Perazin. Thieme, Stuttgart New York, S 159–172

    Google Scholar 

  193. Galdi J, Rieder RO, Silber D, Bonato RR (1981) Genetic factors in the response to neuroleptics in schizophrenia: a pharmacogenetic study. Psychol Med 11: 713–728

    PubMed  CAS  Google Scholar 

  194. Gardos G (1974) Are antipsychotic drugs inter- changeable? J Nerv Ment Dis 5: 343–348

    Google Scholar 

  195. Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456

    PubMed  CAS  Google Scholar 

  196. Grünberger J, Linzmayer L, Cepko H, Saletu B (1986) Pupillometrie im psychopharmakologischen Experiment. Arzneimittelforschung 36: 14 1146

    Google Scholar 

  197. Haase HJ (1977) Therapie mit Psychopharmaka und anderen seelisches Befinden beeinflussenden Medikamenten, 4. Aufl. Schattauer, Stuttgart New York

    Google Scholar 

  198. Harvey JA (1987) Effects of drugs on associative learning. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 1485–1491

    Google Scholar 

  199. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates. Arch Gen Psychiatry 31: 603–608

    Google Scholar 

  200. Itil TM, Paiierson CD, Keskiner A, Holden JM (1974) Comparison of phenothiazine and non- phenothiazine neuroleptics according to psy- chopathology, side effects and computerized EEG. In: Forrest IS, Carr CJ, Usdin E (eds) The phenothiazines and structurally related drugs. Raven Press, New York, pp 499–509

    Google Scholar 

  201. Itil TM, Marasa J, Saletu B, Davis S, Mucciardi AN (1975) Computerized EEG: predictor of outcome in schizophrenia. J Nerv Ment Dis 160: 188203

    Google Scholar 

  202. Itil TM, Shapiro D, Schneider SJ, Francis IB (1981) Computerized EEG as a predictor of drug response in treatment resistant schizophrenics. J Nerv Ment Dis 169: 629–637

    PubMed  CAS  Google Scholar 

  203. Janke W (1980) Psychometric and psychophysiological actions of antipsychotics in men. In: Hoffmeister F, Stille G (eds) Psychotropic agents. Springer, Berlin Heidelberg New York, pp 305–336

    Google Scholar 

  204. Jurna I (1980) Neurophysiological properties of neuroleptic agents in animals. In: Hoffmeister F, Stille G (eds) Psychotropic agents. Springer, Berlin Heidelberg New York, pp 111–175

    Google Scholar 

  205. Kane JM (1984) The use of depot neuroleptics: clinical experience in the United States. J Clin Psychiatry 45: 5–12

    PubMed  CAS  Google Scholar 

  206. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796

    Google Scholar 

  207. Kapfhammer H-P, Ruther E (1988) Depot-Neuroleptika. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  208. Killian GA, Holzman PS, Davis JM, Gibbons R (1984) Effects of psychotropic medication on selected cognitive and perceptual measures. J Abnorm Psychol 93: 58–70

    PubMed  CAS  Google Scholar 

  209. Kornetsky C (1985) Neuroleptic drugs may attenuate pleasure in the operant chamber, but in the schizophrenic’s head they may simply reduce motivational arousal. Behav Brain Sci 8: 173–192

    Google Scholar 

  210. Kreiskott H (1980) Behavioral pharmacology of antipsychotics. In: Hoffmeister F, Stille G (eds) Psychotropic agents. Springer, Berlin Heidelberg New York, pp 59–88

    Google Scholar 

  211. Lauber HL (1967) Pupillometrische Versuche bei Anwendung von Psychopharmaka. Med Welt 18: 572–576

    Google Scholar 

  212. Laurian S, LE PK, Baumann P, Perey M, Gaillard J-M (1981) Relationship between plasma-levels of chlorpromazine and effects on EEG and evoked potentials in healthy volunteers. Pharmacopsychiatry 14: 199–204

    CAS  Google Scholar 

  213. Lehmann HE (1975) Psychopharmacological treatment of schizophrenia. Schizophr Bull 13: 2745

    Google Scholar 

  214. Lehr E (1980) Testing antipsychotic drug effects with operant behavioral techniques. In: Hoff-Meister F, Stille G (eds) Psychotropic agents. Springer, Berlin Heidelberg New York, pp 89–95

    Google Scholar 

  215. Leuschner F, Neumann W, Hempel R (1980) Toxicology of antipsychotic agents. In: Hoffmeister F, Stille G (eds) Psychotropic agents. Springer, Berlin Heidelberg New York, pp 225–265

    Google Scholar 

  216. Loga S, Curry S, Lader M (1975) Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. Br J Clin Pharmacol 2: 197–208

    PubMed  CAS  Google Scholar 

  217. Marder SR, Hawes EM, Putten VAN T, Hubbard JW, Mckay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Psychopharmacology 88: 480–483

    PubMed  CAS  Google Scholar 

  218. May PRA, Goldberg SC (1978) Prediction of schizophrenic patients’ response to pharmacopsychiatry. In: Lipton MA, Dimascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1139–1153

    Google Scholar 

  219. May PRA, Pui I Van T, Yale C, Potepan P, Jenden DJ, Fairchild MD, Goldstein MJ, Dixon WJ (1976) Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis 162: 177–183

    PubMed  CAS  Google Scholar 

  220. May PRA, Puilhn van T, Jenden DJ, Yale,C, Dixon WJ, Goldstein MJ (1981) Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment. Compr Psychiatry 22: 147–152

    CAS  Google Scholar 

  221. Meltzer HY, Busch DA, Fang VS (1983) Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatr Res 9: 271–283

    CAS  Google Scholar 

  222. Möller HJ, Kissling W, Zerssen Von D (1983) Die prognostische Bedeutung des frühen Ansprechens schizophrener Patienten auf Neuroleptika für den weiteren stationären Behandlungsverlauf. Pharmacopsychiatry 16: 46 19

    Google Scholar 

  223. Murphy DL, Shiling DJ, Murray RM (1978) Psychoactive drug responder subgroups: possible contributions to psychiatric classification. In: Lipton MA, Dimascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 807–820

    Google Scholar 

  224. Nedopil N, Ruther E (1981) Initial improvement as predictor of outcome of neuroleptic treatment. Pharmacopsychiatry 14: 205–207

    CAS  Google Scholar 

  225. Niemegeers CJE (1984) Zur Pharmakologie der Antidepressiva und Neuroleptika. Nervenheilkunde 3: 28–32

    Google Scholar 

  226. Oyevwmi LK (1983) Neuroleptics under high risk conditions. Can J Psychiatry 38: 398–402

    Google Scholar 

  227. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522

    PubMed  CAS  Google Scholar 

  228. Randrup A, Kjellberg B, Schiörbing E, Schell-Krüger J, Foc R, Munkvad I (1980) Stereotyped behavior and its relevance for testing neuroleptics. In: Hoffmeister F, Stille G (eds) Psychotropic agents. Springer, Berlin Heidelberg New York, pp 97–110

    Google Scholar 

  229. Rovbicek J (1980) Antipsychotics: neurophysiological properties (in man). In: Hoffmeister F, Stille G (eds) Psychotropic agents. Springer, Berlin Heidelberg New York, pp 178–192

    Google Scholar 

  230. Rom RH, Wolf ME, Deutsch AY (1987) Neurochemistry of midbrain dopamine systems. In: Meltzer HY (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 81–94

    Google Scholar 

  231. Sakurai Y, Takahashi R, Nakahaaa T, Ikenaga H (1980) Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients. Arch Gen Psychiatry 37: 1057–1061

    PubMed  CAS  Google Scholar 

  232. Saletu B (1980) Central measures in schizophrenia. In: Praag Van,HM, Lader MH, Rafaelsen OJ, Sachar EJ (eds) Handbook of biological psychiatry. Part II. Brain mechanisms and abnormal behavior — psychophysiology. Dekker, New York Basel, pp 97–144

    Google Scholar 

  233. Saletu B, Anderer P (1989) EEG-Mapping in der psychiatrischen Diagnose-und Therapieforschung. In: Saletu B (Hrsg) Biologische Psychiatrie. Thieme, Stuttgart New York, S 31–51

    Google Scholar 

  234. Simpson GM, Yadalam K (1985) Blood levels of neuroleptics: state of the art. J Clin Psychiatry 46: 22–28

    PubMed  CAS  Google Scholar 

  235. Simpson GM, Cooper TB, Bark N, Sud I, Lee JH (1980) Effect of antiparkinsonian medication on plasma levels of chlorpromazine. Arch Gen Psychiatry 37: 205–208

    PubMed  CAS  Google Scholar 

  236. Sovner R, DI Mascio A (1978) Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Lipton MA, Dimascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1021–1032

    Google Scholar 

  237. Stille G (1971) Zur Pharmakologie katatonigener Stoffe. Arzneimmittelforschung 6: 800–808

    Google Scholar 

  238. Stille G, HIPPIUS H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika. In: Coper H, Engelmeier MP, Heinrich K, Herz A, Hippius H, Kielholz P (Hrsg) Pharmakopsychiatrie. Neu- Ro-Psychopharmakologie. Thieme, Stuttgart, S 182–191

    Google Scholar 

  239. Strauss JS, Carpenter WT, Bartko JJ (1977) The diagnosis and understanding of schizophre- nia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11: 61–69

    Google Scholar 

  240. Thiels C, Leeds A, Resch F, Goessens L (1983) Wirkungen psychotroper Substanzen auf Embryo and Fetus. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen and Therapie. Springer, Wien New York, S 559–573

    Google Scholar 

  241. Tuma AH, May PRA, Yale C, Forsthye AB (1978) Therapist characteristics and the outcome of treatment in schizophrenia. Arch Gen Psychiatry 35: 81–85

    PubMed  CAS  Google Scholar 

  242. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand [Suppll 367: 69–93

    CAS  Google Scholar 

  243. Van Putten T, May PRA, Jenden DJ (1971) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734

    Google Scholar 

  244. Venables PH (1980) Peripheral measures of schizophrenia. In: Praag Van HM, Lader MH, Rafaelsen OJ, Sachar EJ (eds) Handbook of biological psychiatry, part 3. Dekker, New York Basel, pp 79–95

    Google Scholar 

  245. Wise RA (1978) Catecholamine theories of reward: a critical review. Brain Res 152: 215247

    Google Scholar 

  246. Wise RA (1982) Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 5: 39–87

    Google Scholar 

  247. Woggon B, Baumann U (1983) Multimethodological approach in psychiatric predictor research. Pharmacopsychiatry 16: 175–178

    CAS  Google Scholar 

  248. Wyatt RJ (1976) Biochemistry and schizophrenia. Part IV. The neuroleptics — their mechanism of action: a review of the biochemical literature. Psychopharmacol Bull 12: 5–50

    PubMed  CAS  Google Scholar 

  249. Yadalam KG, Simpson GM (1988) Changing from oral to depot fluphenazine. J Clin Psychiatry 49: 346–348

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. K. Heininger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Sieberns
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Gaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer  & Gerd Laux  & 

  2. Psychiatrische Universitätsklinik, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Wien

About this chapter

Cite this chapter

Heininger, K., Sieberns, S., Gaebel, W. (1992). Pharmakologie. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3282-1_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3282-1_2

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3283-8

  • Online ISBN: 978-3-7091-3282-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation